The European Bank for Reconstruction and Development has provided a 5 million euro ($6.55 million) loan to Geropharm, one of Russia's leading pharmaceutical companies, to help it upgrade its drug manufacturing plant in Obolensk in the Moscow region.
The loan was issued for five years to Geropharm-Bio, a Geropharm subsidiary, the EBRD said in a statement Wednesday. It is expected to help the company meet the Good Manufacturing Practices standard.
The company plans to install a new filling and packaging line for existing products. The company's insulin production will more than double as a result. Geropharm also plans to shift its production line to more profitable drugs.
In 2011, the value of Russia's pharmaceutical market was estimated at nearly $21 billion, with domestically manufactured drugs accounting for only around 22 percent of this amount.
The EBRD has so far invested more than 150 million euros in Russia's pharmaceutical and healthcare industries.
Geropharm is a privately owned manufacturer and distributor of human insulin and other drugs.
Related articles:
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.